Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER_GOV 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Hydralazine × Clear all
NCT00996060 2016-01-18

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

New Mexico Cancer Research Alliance

Phase 1 Completed
29 enrolled
Thoracic

Lung Neoplasms

NCT00575640 2015-03-04

Hydralazine as a Demethylating Agent in Rectal Cancer

University of Arkansas

Phase 1/2 Withdrawn
Gastrointestinal

Rectal Neoplasms

NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡